Related Experiment Video
Updated: Jul 23, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Staring at the onco-exaptation: the two-faced medley of an ancient retrovirus, HERVH
Manvendra Singh1,2, Aleksandra M Kondraskhina2, Laurence D Hurst3
1Max Planck Institute of Multidisciplinary Sciences, City Campus, Göttingen, Germany.
Abstract:
Cell senescence suppresses tumors by arresting cells at risk of becoming malignant. However, this process in turn can affect the microenvironment, leading to acquisition of a senescence-associated secretory phenotype (SASP) that renders senescent cells proinflammatory and results in tumor progression. But how is SASP controlled? In this issue of the JCI, Attig and Pape et al. describe the role of chimeric calbindin 1 (CALB1) transcripts, which are driven by an upstream human endogenous retrovirus subfamily H (HERVH) element. The authors propose that in lung squamous cell carcinoma (LUSC), HERVH-driven isoforms of calbindin (HERVH-CALB1) counteract SASP. As an alternative promoter, HERVH drove calbindin isoforms that prevented cancer cell senescence and associated inflammation, which was associated with better patient survival. We comment on the similarities between HERVH-CALB1-related cellular fitness in cancer and early embryogenesis and discuss the potential benefits of HERVH-driven chimeric transcripts.
Insights
Chimeric calbindin 1 (CALB1) transcripts, driven by a human endogenous retrovirus (HERVH), counteract tumor-promoting inflammation in lung cancer. This HERVH-CALB1 mechanism improves patient survival by preventing senescence-associated secretory phenotype (SASP).
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Cell senescence normally suppresses tumors but can paradoxically promote cancer via the senescence-associated secretory phenotype (SASP).
- The regulatory mechanisms controlling SASP and its impact on tumor progression remain incompletely understood.
- Understanding these mechanisms is crucial for developing novel cancer therapies.
Purpose of the Study:
- To investigate the role of chimeric calbindin 1 (CALB1) transcripts in lung squamous cell carcinoma (LUSC).
- To elucidate the function of human endogenous retrovirus subfamily H (HERVH)-driven CALB1 isoforms in cancer.
- To determine the impact of HERVH-CALB1 on SASP and patient outcomes.
Main Methods:
- Analysis of HERVH-driven chimeric CALB1 transcripts in LUSC.
- Investigation of HERVH-CALB1's effect on cellular senescence and SASP induction.
- Correlation of HERVH-CALB1 expression with patient survival data.
Main Results:
- HERVH elements drive alternative calbindin 1 (CALB1) isoforms (HERVH-CALB1) in LUSC.
- HERVH-CALB1 prevents cancer cell senescence and the associated pro-inflammatory SASP.
- Increased HERVH-CALB1 expression correlates with improved patient survival in LUSC.
Conclusions:
- HERVH-driven chimeric CALB1 transcripts represent a novel mechanism to suppress tumor-promoting inflammation.
- HERVH-CALB1 acts as a tumor suppressor by counteracting SASP in LUSC.
- These findings highlight the potential therapeutic benefits of targeting HERVH-driven transcripts in cancer treatment.
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Retroviruses
Retrovirus Life Cycles
Non-LTR Retrotransposons
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...

